Figure 2.

ODZ10117 inhibits tyrosine phosphorylation of STAT3 in glioblastoma cells. (A–C) Western blot analyses were performed from the glioblastoma cells incubated for 12 h with ODZ10117 in a concentration-dependent manner (A), 40 μM ODZ10117 in a time-dependent manner (B) or for 12 h with ODZ10117 (40 μM) and the known STAT3 inhibitor S3I-201 (100 μM), STA-21 (100 μM), nifuroxazide (100 μM), or AG-490 (150 μM) (C). (D,E) ODZ10117 and the known STAT3 inhibitors were treated for 12 h and then stimulated with IL-6 (20 ng/mL) for 10 min. (F) Immunofluorescence staining was performed using an anti-pY⁷⁰⁵-STAT3 antibody (green) in GBM14 cells incubated for 24 h with vehicle (0.1% DMSO) alone or ODZ10117 (40 μM). Nuclei were stained with DAPI (blue). Arrowheads indicate tyrosine-phosphorylated STAT3 in the nucleus. Scale bars: 20 μm